Nitroxoline impairs tumor progression in vitro and in vivo by regulating cathepsin B activity
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
// Bojana Mirković 1,* , Boštjan Markelc 2,* , Miha Butinar 3,* , Ana Mitrović 1 , Izidor Sosič 1 , Stanislav Gobec 1 , Olga Vasiljeva 3 , Boris Turk 3,4,5 , Maja Čemažar 2 , Gregor Serša 2 and Janko Kos 1,6 1 Faculty of Pharmacy, University of Ljubljana, Ljubljana, Slovenia 2 Department of Experimental Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia 3 Department of Biochemistry and Molecular and Structural Biology, Jožef Stefan Institute, Ljubljana, Slovenia 4 Centre of Excellence for Integrated Approaches in Chemistry and Biology of Proteins, Ljubljana, Slovenia 5 Faculty of Chemistry and Chemical Technology, University of Ljubljana, Ljubljana, Slovenia 6 Department of Biotechnology, Jožef Stefan Institute, Ljubljana, Slovenia * These authors have equally contributed to this work Correspondence to: Bojana Mirković, email: // Janko Kos, email: // Keywords : nitroxoline, cathepsin B, tumor invasion, angiogenesis, metastasis Received : November 01, 2014 Accepted : March 05, 2015 Published : March 30, 2015 Abstract Cathepsin B is a ubiquitously expressed lysosomal cysteine protease that participates in protein turnover within lysosomes. However, its protein and activity levels have been shown to be increased in cancer. Cathepsin B endopeptidase activity is involved in the degradation of extracellular matrix, a process that promotes tumor invasion, metastasis and angiogenesis. Previously, we reported an established antibiotic nitroxoline as a potent and selective inhibitor of cathepsin B. In the present study, we elucidated its anti-tumor properties in in vitro and in vivo tumor models. Tumor and endothelial cell lines with high levels of active cathepsin B were selected for functional analysis of nitroxoline in vitro . Nitroxoline significantly reduced extracellular DQ-collagen IV degradation by all evaluated cancer cell lines using spectrofluorimetry. Nitroxoline also markedly decreased tumor cell invasion monitored in real time and reduced the invasive growth of multicellular tumor spheroids, used as a 3D in vitro model of tumor invasion. Additionally, endothelial tube formation was significantly reduced by nitroxoline in an in vitro angiogenesis assay. Finally, nitroxoline significantly abrogated tumor growth, angiogenesis and metastasis in vivo in LPB fibrosarcoma and MMTV-PyMT breast cancer mouse models. Overall, our results designate nitroxoline as a promising drug candidate for anti-cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tjäderhane, L., Buzalaf, M. A. R., Carrilho, M., & Chaussain, C. (2015) · Caries Research · doi:10.1159/000363582 · Cited by 2,306
Cysteine cathepsins: From structure, function and regulation to new frontiers
Turk, V., Stoka, V., Vasiljeva, O., Renko, M., Sun, T., Turk, B., & Turk, D. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.10.002 · Cited by 1,377 · cited 1×
“In the exopeptidase conformation, two salt bridges bind the loop to the body of the enzyme, in this way limiting the access of extended substrates to the primed sites of the active-site cleft [1].”
Self-citationKelm, J. M., Timmins, N. E., Brown, C. J., Fussenegger, M., & Nielsen, L. K. (2003) · Biotechnology and Bioengineering · doi:10.1002/bit.10655 · Cited by 934
Generation of Multicellular Tumor Spheroids by the Hanging-Drop Method
Timmins, N. E., & Nielsen, L. K. (2007) · Methods in Molecular Medicine™ · doi:10.1007/978-1-59745-443-8_8 · Cited by 241 · cited 1×
“MCF-10A neoT, a c-Ha-ras oncogene transfected human breast epithelial cell line [40], and LPB fibrosarcoma cell line [41], a clonal derivate of methylcholanthrene-induced C57Bl/6 mouse sarcoma tumor were provided by Bonnie F.”
Sevenich, L., Werner, F., Gajda, M., Schurigt, U., Sieber, C., Müller, S., Follo, M., Peters, C., & Reinheckel, T. (2011) · Oncogene · doi:10.1038/onc.2010.387 · Cited by 85
Cited by
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
The Ins and Outs of Cathepsins: Physiological Function and Role in Disease Management
Yadati, T., Houben, T., Bitorina, A., & Shiri-Sverdlov, R. (2020) · Cells · doi:10.3390/cells9071679 · Cited by 541
8-Hydroxyquinolines in medicinal chemistry: A structural perspective
Oliveri, V., & Vecchio, G. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.007 · Cited by 281
Targeting lysosomes in human disease: from basic research to clinical applications
Cao, M., Luo, X., Wu, K., & He, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00778-y · Cited by 225
Chai, Y. L., Chong, J. R., Weng, J., Howlett, D., Halsey, A., Lee, J. H., Attems, J., Aarsland, D., Francis, P. T., Chen, C. P., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12631 · Cited by 73
“In particular, cathepsins B and D have been implicated in various cancers as well as in cellular processes which may be relevant in neurodegeneration, including cell cycle regulation, autophagy and neuroinflammation (5,22,41,46,65).”
Background
Metadata
- Authors
- Mirković, B., Markelc, B., Butinar, M., Mitrović, A., Sosič, I., Gobec, S., Vasiljeva, O., Turk, B., Čemažar, M., Serša, G., & Kos, J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-03-30
- Volume
- 6
- Issue
- 22
- Pages
- 19027-19042
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W1826848231
- Cited by
- 66
- References
- 5
- FWCI
- 2.45
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.